Close Menu

NEW YORK (GenomeWeb News) – Goldman Sachs has upgraded the stock of Agilent Technologies and Bruker, but downgraded Cepheid and Laboratory Corporation of America.

In a report released Sunday about the impending fiscal cliff as well as the global macroeconomic picture, analyst Isaac Ro upgraded the stocks of both Agilent and Bruker to a Buy rating from Neutral, but lowered Cepheid to Neutral from Buy and LabCorp to Sell from Neutral.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.